Poor posterior occlusion identified as a new risk factor for dementia
Medical advances and better knowledge of health have contributed to increased life expectancy and a growing elderly population; with that, …
Medical advances and better knowledge of health have contributed to increased life expectancy and a growing elderly population; with that, …
Syndax Pharmaceuticals has announced that its Phase II trial of revumenib achieved its primary endpoint in certain patients with relapsed …
Kezar Life Sciences has been handed a second clinical hold by the US Food and Drug Administration (FDA) in as …
As the pharmaceutical industry focuses on complex, potentially life changing biologics, lyophilization, or freeze-drying, has become essential for the successful …
After years of teasing an entry into the surgical robotics space, Johnson & Johnson (J&J) MedTech has completed a major …
Recce Pharmaceuticals (Recce) has obtained approval from the Human Research Ethics Committee in Indonesia to initiate a registrational Phase III …
Longboard Pharmaceuticals has commenced the Phase III DEEp OCEAN Study of its investigational oral drug bexicaserin for treating seizures linked …
Syros Pharmaceuticals’ stock has declined sharply for the second time in the past three months as a Phase III trial …
Merck & Co (MSD), Alexion, and AstraZeneca Rare Disease have reported positive topline outcomes from the Phase III KOMET trial, assessing …
As any seasoned expert in the clinical trials field would affirm, it is not enough to have an innovative therapeutic …
Not long after netting $57m in financing, Inflammatix has kick started a clinical trial evaluating its technology for the management …
Novavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its …
Canadian clinical trial company Arch Biopartners has dosed the first patient in Canada in its Phase II clinical trial of …
AbbVie’s stock price fell over 12% after emraclidine, an investigational anti-psychotic being evaluated for the treatment of schizophrenia, failed to …
Neurogene’s stock has dropped by nearly 35% in pre-market trading after a patient in its Rett syndrome gene therapy trial …